$ALKS Headlines Despite Fed concerns, technicals support

New Post Public Reply Private Reply Replies (0) Message Board

Jan 10, 2014 at 9:04 PM

$ALKS Headlines

Despite Fed concerns, technicals support bull case 1:16 p.m. Sept. 17, 2013 - Michael Ashbaugh
Despite Fed concerns, technicals support bull case 12:02 p.m. Sept. 17, 2013 - Michael Ashbaugh
Biogen, InterMune, Alkermes all make stock waves with earnings 1:28 p.m. July 25, 2013 - Russ Britt
Reading the fine print turns initial Alkermes share loss into a gain 10:49 a.m. May 23, 2013 - Russ Britt
Health stocks ride potential, momentum to a higher close 3:37 p.m. April 19, 2013 - Russ Britt
Alkermes shares surge on positive results for depression disorder drug 12:20 p.m. April 17, 2013 - Russ Britt
S&P, Dow hold tightly to resistance 11:04 a.m. Oct. 8, 2012 - Michael Ashbaugh
Stocks to watch Thursday: Alkermes, Tilly’s 5:42 a.m. May 31, 2012 - MarketWatch
Amylin rallies 20% on diabetes drug approval 11:18 a.m. Jan. 30, 2012 - Val Brickates Kennedy
U.S. futures lower; Pep Boys, Thomas & Betts gain 9:30 a.m. Jan. 30, 2012 - Kate Gibson
PharMerica dives, Amylin surges after hours 7:11 p.m. Jan. 27, 2012 - Carla Mozee
Stocks to Watch Monday: Alkermes, Amylin 6:10 p.m. Jan. 27, 2012 - David B. Wilkerson
FDA approves Amylin's Bydureon diabetes drug 5:56 p.m. Jan. 27, 2012 - MarketWatch.com
Alkermes resumes trading, up 4.7% after hours 4:19 p.m. Jan. 27, 2012 - Carla Mozee
Amylin shares resume trading, up 15% after hours 4:16 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin drug Bydureon 4:06 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amlyin, Alkermes to resume trade at 4:15 p.m. EST 4:01 p.m. Jan. 27, 2012 - Carla Mozee
FDA approves Alkermes/Amylin diabetes drug 3:54 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Alkermes, Amylin halted as FDA deadline approaches 2:17 p.m. Jan. 27, 2012 - Val Brickates Kennedy
Amylin, Alkermes shares halted pending news 2:05 p.m. Jan. 27, 2012 - Wallace Witkowski

Is This the Top for Alkermes Plc (ALKS)? - Tale of the Tape 8:31 a.m. Jan. 9, 2014 - Zacks.com
J.P. Morgan Top Biotechnology Stocks to Buy for 2014 7:39 a.m. Jan. 8, 2014 - 247WallSt.com
Alkermes Announces Advances in Late-Stage CNS Pipeline 6:02 a.m. Jan. 8, 2014 - benzinga.com
Notice of Allowance Received by Alkermes - Analyst Blog 4:21 p.m. Jan. 7, 2014 - Zacks.com
Alkermes Receives Notice of Allowance of US Patent for Novel Fumarate Prodrug for MS 6:04 a.m. Jan. 6, 2014 - benzinga.com
Analysts Issue Bullish Biotech Outlooks for '14, Except Goldman, Which Is Negative 6:03 a.m. Jan. 6, 2014 - TheStreet.com
Insider Trading Alert - UNP, FIS, JBL, MAT And ALKS Traded By Insiders 10:01 a.m. Dec. 30, 2013 - TheStreet.com
Alkermes: 7 Different Insiders Have Sold Shares This Month 2:45 a.m. Dec. 30, 2013 - Seeking Alpha
Alkermes Larger Than S&P 500 Component Legg Mason 4:38 p.m. Dec. 27, 2013 - TheStreet.com
Ireland Home To Several Fast Growing Health Care Names 4:02 p.m. Dec. 24, 2013 - Investors Business Daily
Alkermes plc (ALKS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 16, 2013 - Zacks.com
Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting 6:13 a.m. Dec. 9, 2013 - benzinga.com
3 Stocks Dragging In The Health Care Sector 12:06 p.m. Dec. 5, 2013 - TheStreet.com
Analysts Actions: ALKS CELG HK ORCL S 8:11 a.m. Dec. 5, 2013 - TheStreet.com
Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews 4:28 a.m. Dec. 3, 2013 - Zacks.com
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook 4:28 a.m. Dec. 3, 2013 - Zacks.com
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook 4:28 a.m. Dec. 3, 2013 - Zacks.com
Insider Trading Alert - CBI, IPG, SAPE, ALKS And CSCO Traded By Insiders 1:15 p.m. Nov. 25, 2013 - TheStreet.com
Insider Trading Alert - CBI, IPG, SAPE, ALKS And CSCO Traded By Insiders 1:03 p.m. Nov. 25, 2013 - TheStreet.com
Can Alkermes Plc (ALKS) Continue to Rise? - Tale of the Tape 11:19 a.m. Nov. 25, 2013 - Zacks.com

Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD 8:00 a.m. Jan. 8, 2014 - PR Newswire
Alkermes Announces Advances With Its Late-Stage CNS Pipeline 7:00 a.m. Jan. 8, 2014 - BusinessWire
Alkermes' Corporate Presentation to be Webcast at the 32nd Annual J.P. Morgan Healthcare Conference 4:00 p.m. Jan. 7, 2014 - BusinessWire
Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis 7:00 a.m. Jan. 6, 2014 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion 12:24 p.m. Dec. 10, 2013 - PR Newswire
Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP Meeting 7:00 a.m. Dec. 9, 2013 - BusinessWire
Stock Price Movement and Senior Notes Redemption - Research Report on Valeant, Edwards Lifesciences, Alkermes, Mallinckrodt, and Dr. Reddy's 8:00 a.m. Dec. 6, 2013 - PR Newswire
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes 8:00 a.m. Nov. 22, 2013 - PR Newswire
Before the Bell Scans: Theravance Inc., Alkermes PLC, Celsion Corp., and Hospira Inc. 6:23 p.m. Nov. 14, 2013 - PR Newswire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Advancing Pipelines, Liquidity Growth, Cost-reduction Initiatives and Breakthrough Studies - Research Report on Alkermes, Abiomed, Gentium, Amarin, and VIVUS 8:00 a.m. Nov. 6, 2013 - PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - BusinessWire
Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013 6:00 a.m. Oct. 31, 2013 - BusinessWire
New Appointments, Upcoming Earnings Releases, Regulatory Approvals, Status Updates and Informative Resources for New Treatment Options - Research Report on Mylan, Alkermes, Salix, Ligand and Hospira 8:31 a.m. Oct. 30, 2013 - PR Newswire
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013 3:00 p.m. Oct. 24, 2013 - BusinessWire
Pre-Market Review: Alkermes PLC, Hospira Inc., Celsion Corp., and Theravance Inc. 8:30 a.m. Oct. 24, 2013 - PR Newswire
Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 10, 2013 - BusinessWire
Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder 6:00 a.m. Oct. 9, 2013 - BusinessWire
Alkermes Announces Completion of Patient Enrollment in Pivotal Phase 3 Study of Aripiprazole Lauroxil 6:00 a.m. Oct. 8, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Air Canada-CAE Scholarship Drives Women in Aviation

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

FirstLight Home Care Reaches 300 Locations Milestone

FirstLight Celebrates a Major Milestone FirstLight Home Care just hit a big milestone, reaching a whopping 300 locations. That's not just a feather in their cap; it's a sign that their approach to senior care is resonating with communities across the map. The company is kicking off a celebration tour, cleverly dubbed the Best Days Tour, highlighting each step forward with...

Grinnell Poll Unveils Shifting Confidence, Crisis Fears

Confidence in Fair Elections Climbs Amid Turmoil You know what, there are days when you just gotta chuckle at the way things unfold. Take the latest Grinnell College Poll: it tells us Americans are feeling more upbeat about their votes being counted right. Now, that's a breath of fresh air in a space that's been clogged with doubt for way too long. Pessimism on...

Step into Fear: Dead by Daylight in Moreno Valley

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

California Exodus: Companies Flee Amid Wealth Tax Fears

Businesses Escaping the Golden State Proposition 40—the looming specter over California's business landscape. This so-called billionaire tax has stirred quite the storm, and from where I'm sitting, it's no surprise folks are heading for the exits. Cummings & Cummings Law reports a jaw-dropping 12-fold increase in companies scooting out of California and making a beeline...

Royce Micro-Cap Trust: Navigating Small-Cap Waves

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Data Centers Drive Surge in Power and Cooling Demand

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Sodium Silicate Market To Hit $7.4B by 2031

What's Fueling the Market's Climb? I tell ya, sodium silicate might not be a household name, but it's trekking upwards with a clear purpose. By 2031, this market's expected to touch $7.4 billion from $6 billion in 2026 at a neat 4.4% CAGR. For an old-school trader like me, that's the kind of steady growth that catches my eye. The driving factors? Well, it’s more than...